ERBB2 and triple-negative breast carcinoma: 12–15% of all tumors lack immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [1] and are therefore termed triple-negative breast cancers (TNBC).